HIV+Hep in the News

CBO: Expanding hepatitis C treatment could save money

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, told Inside Health Policy the report is a start, but still incomplete, noting that outreach, implementation and coverage of those outside of Medicaid were left out of the analysis. But he said the report reinforced that it is cost effective to cure people with hepatitis C. “It states the obvious that when you treat people with hepatitis C, it’s definitely cost saving to the health care system,” Schmid said.

read more

R.I. General Assembly passes legislation to help expedite access to HIV prevention meds

A year’s worth of generic, daily PrEP in pill form cost about $360 in 2022. But the new legislation could also save the health care system money by preventing the need for costlier HIV treatments. A 2022 report from the HIV+Hepatitis Policy Institute estimated that, over 10 years, PrEP could prevent enough infections to save $2.27 billion in patient treatment costs.

read more

CMS shifting gears to focus on coding to ensure cost-free preventive coverage

Carl Schmid, executive director of the HIV+Hepatits Policy Institute, said that while it’s good CMS is interested in addressing the coding problems that advocates identified, the agency still needs to do more. “Unfortunately, it isn’t enough. People are still being charged for cost-sharing,” Schmid said at a recent congressional briefing on HIV.

read more

Nevada enforcing copay accumulator ruling in 2025 health benefit plan

“Even though insurers are collecting assistance from drug makers, those sums are not ‘counted’ by the patient’s insurance company, leaving the patient unable to pay for their treatment when the manufacturer assistance ends or the patient attempts to access other healthcare items or services,” Carl Schmid, executive director of the HIV + Hepatitis Policy Institute, wrote March 12 to state insurance commissioners.

read more

The latest news about HIV infection rates in the US is both good and bad

“While we would have liked to see improved outcomes, federal funding for CDC HIV prevention and the Ryan White HIV/AIDS care and treatment program, along with other critical programs, has remained flat for years,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “The only increases have been for the Ending the HIV Epidemic initiative, and even that program hasn’t received the increases it needs to be successful. Without significant increases for care and treatment, and prevention programs, including those for PrEP, sadly we will continue to experience only small drops in the number of new diagnoses, and racial and ethnic disparities will persist. As a nation, we can and must do better.”

read more

Pin It on Pinterest

Share This